Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00503360 | Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension | PHASE1 | COMPLETED | 80 | — | — | Apr 1, 2007 | - | Apr 24, 2008 | 1 | Australia |
| Name | Type | Description |
|---|---|---|
| SAD448 | DRUG | - |
Key inclusion criteria: * Males and females, 18 - 65 years of age, with ocular hypertension * Females must be post-menopausal or surgically sterile Key exclusion criteria: * Diagnosis of glaucoma in either eye * A history of or current eye conditions or medical problems that would prohibit the us...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Bimatoprost, AGN-193408 |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol , 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test - Bimatoprost 0.01%, Reference - LUMIGAN, Bimatoprost , 0.01%, LUMIGAN 0.01% |
| Glaukos Corp | GKOS | 1 | — | Travoprost |